Depósito Académico >
CIMA (Centro de Investigación Médica Aplicada) >
Área de Oncología >
DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista >
Please use this identifier to cite or link to this item:
|Title: ||The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience|
|Author(s) : ||Rodriguez, J. (J)|
Conde, E. (E.)
Gutierrez, A. (Antonio)
Arranz, R. (R.)
Leon, A. (Angel)
Marin, J. (Julián)
Bendandi, M. (Maurizio)
Albo, C. (Carmen)
Caballero, M.D. (M.D.)
|Issue Date: ||2007|
|Publisher: ||Oxford University Press|
|Citation: ||Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007 Apr;18(4):652-657.|
|Keywords: ||Autologous stem-cell transplantation|
Peripheral T-cell lymphoma
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas associated with poor prognosis with standard chemotherapy. Consolidation with autologous stem-cell transplantation (ASCT) may improve survival. We present 74 patients transplanted in first complete response (CR) from the Spanish Lymphoma and Autologous Transplantation Group cooperative group.
PATIENTS AND METHODS:
Median age was 46 years. Eighty-eight percent presented advanced (III-IV) Ann Arbor stage; 53% had B symptoms; 52% had high lactate dehydrogenase; 65% had two or three risk factors of the adjusted-International Prognostic Index; 58% presented a high Tumor score and in 14% more than two adverse factors of the Prognostic Index for peripheral T-cell lymphoma (PIT) were observed.
With a median follow-up of 67 months from diagnosis, the 5-year overall survival (OS) was 68% and progression-free survival (PFS) reached 63%. The multivariate analysis showed that the only factor associated with a shorter OS and PFS was the presence of more than two risk factors from the PIT risk system.
In a retrospective study with a prolonged follow-up, consolidation with ASCT in CR patients who had presented unfavorable prognostic factors at diagnosis substantially increased the OS and PFS when compared with conventional chemotherapy. The PIT risk system identified 14% of patients without benefit from ASCT consolidation. Thus, other innovative therapies are still necessary in certain cases.|
|Publisher version (URL): ||http://annonc.oxfordjournals.org/content/18/4/652|
|Appears in Collections:||DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista|
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.